INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant drop in its stock price due to disappointing clinical trial results for its lead drug candidate, ersodetug [1] Company Overview - Rezolute, Inc. is a biopharmaceutical company focused on developing treatments for congenital hyperinsulinism [1] - The company's lead drug candidate is ersodetug, which recently underwent a Phase 3 clinical trial [1] Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug failed to meet both its primary and key secondary endpoints [1] - The highest dose of the drug showed reductions in hypoglycemia events that were not statistically significant compared to placebo [1] Stock Performance - Following the trial results, Rezolute's stock (RZLT) experienced a dramatic decline, dropping from approximately $10.94 to an intraday low of around $0.90, representing an approximate 85-90% decrease [1] - Trading was halted under Nasdaq's volatility controls due to the sharp decline [1]